Tech Company Financing Transactions
Apollomics Funding Round
Apollomics, operating out of Foster City, secured $124.2 million in funding from Ping An Group and private investors.
Transaction Overview
Company Name
Announced On
11/10/2020
Transaction Type
Venture Equity
Amount
$124,200,000
Round
Series C
Investors
Ping An Group (Lead Investor) (Dong Liu)
Proceeds Purpose
The Company Will leverage the funding to accelerate the clinical trials of two flagship drug candidates - APL-101, a selective c-MET inhibitor, that inhibits various tumours; and APL-106, a targeted E-selectin antagonist used to inhibit leukaemia that received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
989 East Hillsdale Blvd. 220
Foster City, CA 94404
USA
Foster City, CA 94404
USA
Phone
Website
Email Address
Overview
At Apollomics, we are a purpose driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Guo-Liang Yu
Chief Financial Officer
Wilson Cheung
Chief Medical Officer
Fabio Benedetti
General Manager
Qian Shi
President
Sanjeev Redkar
Vice President
Scott Houston
VP - Manufacturing
Yuling Li
Browse more venture capital transactions:
Prev: 11/10/2020: Ambrx venture capital transaction
Next: 11/10/2020: Precision Opinion venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs